• Authors: Ouranidis A. et al.
  • Year: 2021
  • Journal: Vaccines (Basel) 9 890
  • Applications: in vitro / mRNA / jetMESSENGER
  • Cell type: CHO-K1
    Description: Chinese hamster ovary cells


- The synthesized mRNA within the lipid carrier (mRNA/jetMESSENGER® ratio 1:2), was eventually used for the transient transfection CHO-K1 cells. - After 48 h of incubation, transfected CHO-K1 cells were selected out, the cytoplasmic RNA was isolated and assessed by RT-PCR analysis, for the steady-state level assessment of TZM RNA transcripts that were encoded by the Heavy and Light Chains, respectively. - After 72 h, the culture supernatant of transfected CHO-K1 cells was collected, containing the TZM antibody.


Administration of mRNA against SARS-CoV-2 has demonstrated sufficient efficacy, tolerability and clinical potential to disrupt the vaccination field. A multiple-arm, cohort randomized, mixed blind, placebo-controlled study was designed to investigate the in vivo expression of mRNA antibodies to immunosuppressed murine models to conduct efficacy, safety and bioavailability evaluation. Enabling 4.0 tools we reduced animal sacrifice, while interventions were designed compliant to HARRP and SPIRIT engagement: (a) Randomization, blinding; (b) pharmaceutical grade formulation, monitoring; (c) biochemical and histological analysis; and (d) theoretic, statistical analysis. Risk assessment molded the study orientations, according to the ARRIVE guidelines. The primary target of this protocol is the validation of the research hypothesis that autologous translation of Trastuzumab by in vitro transcribed mRNA-encoded antibodies to immunosuppressed animal models, is non-inferior to classical treatments. The secondary target is the comparative pharmacokinetic assessment of the novel scheme, between immunodeficient and healthy subjects. Herein, the debut clinical protocol, investigating the pharmacokinetic/pharmacodynamic impact of mRNA vaccination to immunodeficient organisms. Our design, contributes novel methodology to guide the preclinical development of RNA antibody modalities by resolving efficacy, tolerability and dose regime adjustment for special populations that are incapable of humoral defense.